Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 16.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 16.5 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from Neurocrine Biosciences, Inc. and Supernus Pharmaceuticals.

Annual Psychiatric Times® World CME Conference™

Release Date: November 30, 2020
Expiration Date: November 30, 2021

Activity Overview

This online, on-demand, virtual symposium brings together renowned experts in the field of psychiatry. With the emergence of new therapeutic strategies, we now have more options for improving quality of life for people diagnosed with psychiatric disorders. As the field continues to progress, it is important for mental health care providers to understand the current clinical data and best practices when caring for their patients.

The Annual Psychiatric Times® World CME Conference™ is an event specifically designed to help you apply new evidence-based clinical concepts in psychiatry to real-world clinical practice. This 3-day meeting features expert presentations and panel discussions addressing emerging psychiatric treatments and the newest clinical trial data, and best practices for managing challenging psychiatric diagnoses. Topics include mood disorders, anxiety disorders, eating disorders, postpartum depression, substance abuse disorders, and more. This experience provides the ideal curriculum with a focus on challenging patient case scenarios, integrating relevant evidence into real-world patient management, and comparing your practices with those of experts and peers.

This educational activity is an archive of the live virtual symposium held on October 15-17, 2020.

Acknowledgement of Commercial Support

 

This activity is supported by educational grants from Neurocrine Biosciences, Inc. and Supernus Pharmaceuticals.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward psychiatrists and other health care professionals who are interested in the diagnosis and management of psychiatric disorders.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Discuss appropriate screening and diagnostic approaches for psychiatric disorders
  • Describe current strategies and recent advances in treating psychiatric disorders
  • Explain the mechanism of action of therapeutic agents used to treat psychiatric disorders
  • Identify strategies to manage treatment-related adverse events in psychiatric disorders
  • Describe the impact of psychiatric conditions on patients’ quality of life
  • Outline multidisciplinary care strategies to optimize patient outcomes in psychiatric disorders

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Anita Clayton, MD
Anita Clayton, MD
Professor and Chair
Department of Psychiatry and Neurobehavioral Sciences
University of Virginia
Charlottesville, VA

Disclosures: Grant/Research Support: Acadia Pharmaceuticals, Allergan, Endoceutics, Janssen Pharmaceuticals, Sage Therapeutics; Consultant: Acadia Pharmaceuticals, Alkermes, Allergan, AMAG Pharmaceuticals, Daré Bioscience, Fabre-Kramer Pharmaceuticals, MedAvante-ProPhase, Ovoca Bio, Palatin Technologies, PureTech Health, S1 Biopharma, Sage Therapeutics, Sprout Pharmaceuticals, Takeda/Lundbeck; Shareholder: Euthymics Bioscience, S1 Biopharma.

Roger McIntyre, MD
Roger McIntyre, MD
Professor, Psychiatry and Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Executive Director
Brain and Cognition Discovery Foundation
Toronto, Canada

Disclosures: Consultant: Allergan, Janssen Pharmaceuticals, Lundbeck, Minerva Neurosciences, Neurocrine Biosciences, Otsuka Pharmaceutical, Pfizer, Purdue University, Shire, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company; Speakers’ Bureau: Allergan, Janssen Pharmaceuticals, Lundbeck, Minerva Neurosciences, Neurocrine Biosciences, Otsuka Pharmaceutical, Pfizer, Purdue University, Shire, Sunovion Pharmaceuticals, Takeda Pharmaceutical Company.

John J. Miller, MD
John J. Miller, MD
Medical Director, Brain Health
Editor-in-Chief, Psychiatric Times®
Staff Psychiatrist, Seacoast Mental Health Center
Consulting Psychiatrist, Exeter Hospital
Exeter, NH
Consulting Psychiatrist, Insight Meditation Society
Barre, MA

Disclosures: Consultant: Janssen Pharmaceuticals, Sunovion Pharmaceuticals; Speakers’ Bureau: Allergan, Intra-Cellular Therapies, Neurocrine Biosciences, Otsuka Pharmaceutical, Sunovion Pharmaceuticals, Teva Pharmaceuticals.

Sanjai Rao, MD
Sanjai Rao, MD
Associate Clinical Professor of Psychiatry
University of California, San Diego
Psychiatrist
VA San Diego Healthcare System
San Diego, CA

Disclosures: Consultant: Alkermes, Janssen Pharmaceuticals; Speakers’ Bureau: Alkermes, Janssen Pharmaceuticals, Neurocrine Biosciences, Otsuka Pharmaceutical, Sunovion Pharmaceuticals.

Chris Aiken, MD
Chris Aiken, MD
Director, Mood Treatment Center
Instructor in Clinical Psychiatry
Wake Forest University School of Medicine
Winston-Salem, NC

Disclosures: Chris Aiken, MD, has no relevant financial relationships with commercial interests to disclose.

Peter F. Buckley, MD
Peter F. Buckley, MD
Interim Senior Vice President, VCU Health Sciences
Interim Chief Executive Officer, VCU Health System
Dean, VCU School of Medicine
Executive Vice President, Medical Affairs, VCU Health System
Richmond, VA

Disclosures: Peter F. Buckley, MD, has no relevant financial relationships with commercial interests to disclose.

Shannon Clare Carlin, MA, AMFT
Shannon Clare Carlin, MA, AMFT
Director, Training and Supervision
MAPS Public Benefit Corporation
Multidisciplinary Association for Psychedelic Studies (MAPS)
Santa Cruz, CA

Disclosures: Shannon Clare Carlin, MA, AMFT, has no relevant financial relationships with commercial interests to disclose.

Christoph U. Correll, MD
Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY
Investigator, Center for Psychiatric Neuroscience
Feinstein Institute for Medical Research
Manhasset, NY
Medical Director, Recognition and Prevention (RAP) Program
Department of Psychiatry
The Zucker Hillside Hospital
Glen Oaks, NY

Disclosures: Grant/Research Support: Janssen Pharmaceuticals, Takeda Pharmaceutical Company; Consultant: Consultant: Acadia Pharmaceuticals, Alkermes, Allergan, Angelini Pharma, Axsome Therapeutics, Gedeon Richter, Gerson Lehrman Group, Intra-Cellular Therapies, Janssen/J&J, LB Pharmaceuticals, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine Biosciences, Noven, Otsuka Pharmaceutical, Pfizer, Recordati Pharmaceuticals, ROVI Pharmaceuticals , Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Takeda Pharmaceutical Company, Teva Pharmaceuticals; Shareholder: LB Pharmaceuticals.

Melissa P. DelBello, MD, MS
Melissa P. DelBello, MD, MS
Dr. Stanley and Mickey Kaplan Professor
Chair, Psychiatry & Behavioral Neuroscience
University of Cincinnati
Cincinnati, OH

Disclosures: Grant/Research Support: Acadia Pharmaceuticals, Allergen, Janssen/J&J, Lundbeck, Pfizer, Otsuka Pharmaceutical, Sunovion Pharmaceuticals, Supernus Pharmaceutical; Speakers’ Bureau: Alkermes, Allergen, Assurex Health, CMEology, Johnson & Johnson, Lundbeck, Neuronetics, Otsuka Pharmaceutical, Pfizer, Sunovion Pharmaceuticals, Supernus Pharmaceuticals.

Karl Doghramji, MD
Karl Doghramji, MD
Professor of Psychiatry, Neurology, and Medicine
Sidney Kimmel Medical College at Thomas Jefferson University
Medical Director, Jefferson Sleep Disorders Center
Program Director, Fellowship in Sleep Medicine
Thomas Jefferson University Hospital
Philadelphia, PA

Disclosures: Grant/Research Support: Eisai, Harmony Biosciences, Inspire; Consultant: Eisai, Harmony Biosciences, Jazz Pharmaceuticals, Merck & Co, Pfizer, Teva Pharmaceuticals; Shareholder: Merck & Co.

Paul P. Doghramji, MD, FAAFP
Paul P. Doghramji, MD, FAAFP
Senior Attending Physician, Collegeville Family Practice
Medical Director, Health Services, Ursinus College
Collegeville, PA

Disclosures: Consultant: Eisai; Speakers’ Bureau: Allergan, Harmony Biosciences; Shareholder: Pfizer.

Nassir Ghaemi, MD
Nassir Ghaemi, MD
Professor of Psychiatry
Tufts University School of Medicine
Lecturer on Psychiatry
Harvard Medical School
Boston, MA

Disclosures: Shareholder: Novartis.

Joseph F. Goldberg, MD
Joseph F. Goldberg, MD
Clinical Professor of Psychiatry
Icahn School of Medicine at Mount Sinai
New York, NY
Director, Affective Disorders Research Program
Silver Hill Hospital
New Canaan, CT

Disclosures: Consultant: BioXCel, Otsuka Pharmaceutical, Sage Pharmaceuticals, Sunovion Pharmaceuticals; Speakers’ Bureau: Allergan, Intracellular Therapies, Otsuka Pharmaceutical, Sunovion Pharmaceuticals.

David A. Gorelick, MD, PhD, DLFAPA, FASAM
David A. Gorelick, MD, PhD, DLFAPA, FASAM
Professor of Psychiatry
University of Maryland School of Medicine
Baltimore, MD
Editor-in-Chief, Journal of Cannabis Research

Disclosures: David A. Gorelick, MD, PhD, DLFAPA, FASAM, has no relevant financial relationships with commercial interests to disclose.

Carlos Grilo, PhD
Carlos Grilo, PhD
Professor of Psychiatry and of Psychology
Director, Program for Obesity Weight and Eating Research (POWER)
Yale School of Medicine
New Haven, CT

Disclosures: Consultant: Shire, Sunovion Pharmaceuticals.

Mark B. Hamner, MD
Mark B. Hamner, MD
Professor, Department of Psychiatry and Behavioral Sciences
Medical University of South Carolina
Medical Director, Posttraumatic Stress Disorder Clinical Team
Ralph H. Johnson Department of Veterans Affairs Medical Center
Charleston, SC

Disclosures: Consultant: Otsuka Pharmaceutical.

Robin A. Hurley, MD, FANPA
Robin A. Hurley, MD, FANPA
Associate Chief of Staff, Research and Academic Affairs
Professor, Wake Forest School of Medicine
Departments of Psychiatry and Radiology
Senior Liaison for VA Affairs, Office of the Dean
VISN 6 MIRECC Associate Director, Education VISN 6 Academic Affiliations Officer Salisbury VAMC Salisbury, NC

Disclosures: Robin A. Hurley, MD, FANPA, has no relevant financial relationships with commercial interests to disclose.

Brian Koffman, MDCM, MS Ed
Brian Koffman, MDCM, MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.
Olathe, KS

Disclosures: Consultant: Janssen Pharmaceuticals, Novartis, Verastem Oncology; Speakers’ Bureau: Bristol Myers Squibb, TG Therapeutics; Shareholder: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Gilead Sciences, Johnson & Johnson, MEI Pharma, Miragen Therapeutics, VO, Portola Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics.

Thomas Kosten, MD
Thomas Kosten, MD
Professor of Psychiatry, Neuroscience, Pharmacology, Immunology, and Rheumatology
Jay H. Waggoner Endowed Chair
Director, Division of Alcohol and Addiction Psychiatry
Founding Co-Director, Institute for Clinical & Translational Research
Baylor College of Medicine
Houston, TX
Distinguished Professor of Psychiatry
Peking University School of Medicine
Peking, China

Disclosures: Consultant: Alkermes, Amygdala Neurosciences, Aptinyx, Astellas Pharma, BioXcel Therapeutics, Braeburn Pharmaceuticals, Data Analytics, Embera NeuroTherapeutics, Epiodyne, Indivior, Intra-Cellular Therapies, Mallinckrodt, Medscape, Nektar Therapeutics, Nirsum Labs, Novartis, Opiant Pharmaceuticals, Otsuka Pharmaceutical, Phenex Pharmaceuticals AG, Promentis Pharmaceuticals, Sage Therapeutics, United Neuroscience, US WorldMeds.

Rajnish Mago, MD
Rajnish Mago, MD
Clinical Professor of Psychiatry
SUNY Upstate Medical University
Syracuse, NY
Clinical Assistant Professor of Psychiatry
University of Pennsylvania
Philadelphia, PA

Disclosures: Shareholder: Johnson and Johnson; Other: Partial Travel Expenses: Intas Pharmaceuticals Ltd, India.

Carla Marienfeld, MD
Carla Marienfeld, MD
Associate Clinical Professor of Psychiatry
University of California, San Diego
La Jolla, CA

Disclosures: Carla Marienfeld, MD, has no relevant financial relationships with commercial interests to disclose.

Guy Maytal, MD
Guy Maytal, MD
Assistant Professor of Clinical Psychiatry
Chief, Integrated Care and Psycho-Oncology
Weill Cornell Medicine/NewYork Presbyterian Hospital
New York, NY

Disclosures: Guy Maytal, MD, has no relevant financial relationships with commercial interests to disclose.

Heidi Moawad, MD
Heidi Moawad, MD
Associate Editor, Humanities, Neurology
Clinical Assistant Professor, Division of Medical Education
Case Western Reserve University School of Medicine
Cleveland, OH

Disclosures: Heidi Moawad, MD, has no relevant financial relationships with commercial interests to disclose.

David N. Osser, MD
David N. Osser, MD
Associate Professor of Psychiatry
Harvard Medical School
Attending Psychiatrist
Veterans Affairs Boston Healthcare System
Brockton, MA

Disclosures: David N. Osser, MD, has no relevant financial relationships with commercial interests to disclose.

Jennifer L. Payne, MD
Jennifer L. Payne, MD
Associate Professor of Psychiatry and Behavioral Sciences
Director, Women's Mood Disorders Center
Johns Hopkins Medicine
Baltimore, MD

Disclosures: Consultant: Janssen Pharmaceuticals.

Sheldon H. Preskorn, MD
Sheldon H. Preskorn, MD
Professor, Department of Psychiatry and Behavioral Sciences
University of Kansas School of Medicine
Wichita, KS

Disclosures: Consultant: BioXcel Therapeutics, Janssen Pharmaceuticals, Sunovion Pharmaceuticals; Speakers’ Bureau: Eisai, Janssen Pharmaceuticals, Sunovion Pharmaceuticals.

Anthony L. Rostain, MD, MA
Anthony L. Rostain, MD, MA
Professor of Psychiatry and Pediatrics
Cooper Medical School of Rowan University
Chair and Chief, Department of Psychiatry and Behavioral Health
Cooper University Health Care
Camden, NJ

Disclosures: Consultant: Arbor Pharmaceuticals, National Football League, Shire/Takeda Pharmaceutical Company, Tris Pharma.

Jeffrey R. Strawn, MD, FAACAP
Jeffrey R. Strawn, MD, FAACAP
Associate Professor of Psychiatry and Pediatrics
Associate Vice Chair of Research
Director, Anxiety Disorders Research Program
Department of Psychiatry & Behavioral Neuroscience
University of Cincinnati
Cincinnati, OH

Disclosures: Grant/Research Support: Allergan, Neuronetics, Otsuka Pharmaceutical; Consultant: Myriad Genetics.

Michael Thase, MD
Michael Thase, MD
Professor of Psychiatry Director, Mood and Anxiety Section
Perelman School of Medicine, University of Pennsylvania
Director, Mood Disorders Research
Corporal Michael J. Crescenz Veterans Affairs Medical Center
Philadelphia, PA

Disclosures: Grant/Research Support: Acadia Pharmaceuticals, Agency for Healthcare Research and Quality, Alkermes, Allergan, Assurex Health, Avanir Pharmaceuticals, Axsome Therapeutics, Intra-Cellular Therapies, J&J, Janssen Pharmaceuticals, National Institute of Mental Health, Otsuka Pharmaceutical, Patient- Centered Outcomes Research Institute, Takeda Pharmaceutical Company; Consultant: Acadia Pharmaceuticals, Akili, Alkermes, Allergan, Cerecor, Fabre-Kramer Pharmaceuticals, Gerson Lehrman Group, Guidepoint Global, H. Lundbeck, J&J, Jazz Pharmaceuticals, moksha8 Pharmaceuticals, Nestle, Neuralstem, Novartis, Otsuka Pharmaceutical, Pfizer, Sage Pharmaceuticals, Sunovion Pharmaceuticals.

Sidney Zisook, MD
Sidney Zisook, MD
Distinguished Professor of Psychiatry
Director, Residency Training Program
University of California, San Diego
La Jolla, CA

Disclosures: Grant/Research Support: Compass LTD; Consultant: Defender Pharmaceuticals.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
28293031
Filter By